Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Lantern Pharma advances collaboration with Georgetown University for LP-184 » 07:51
10/05/20
10/05
07:51
10/05/20
07:51
LTRN

Lantern Pharma

$20.50 /

-0.39 (-1.87%)

Lantern Pharma announced…

Lantern Pharma announced the advancement of its collaboration with Georgetown University for LP-184, a small molecule drug candidate currently in preclinical development for certain genomically defined solid tumors, including prostate and pancreatic cancers. The next phase of the collaboration and research program with Georgetown will focus on a larger set of PDX models and help pinpoint the specific mechanism of action, and seek confirmatory validation of the role of PTGR1 and the genetic mutations driving the DNA damage repair pathways that make the drug highly potent in these cancers. Research will also focus on completing the acquisition of detailed genomic information in prostate cancers, which will involve work in animal models and cell lines that have been edited to under and over express key driver genes.

ShowHide Related Items >><<
LTRN Lantern Pharma
$20.50 /

-0.39 (-1.87%)

LTRN Lantern Pharma
$20.50 /

-0.39 (-1.87%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$20.50 /

-0.39 (-1.87%)

Hot Stocks
Lantern Pharma announces research agreement with Fox Chase Cancer Center » 07:56
09/22/20
09/22
07:56
09/22/20
07:56
LTRN

Lantern Pharma

$16.50 /

+0.2 (+1.23%)

Lantern Pharma announced…

Lantern Pharma announced a collaboration and research agreement with Fox Chase Cancer Center for the further development of Lantern's LP-184 in pancreatic cancer. Based in Philadelphia, Fox Chase is a leading research center for pancreatic cancers and one of the four original cancer centers to receive comprehensive cancer center designation from the National Cancer Institute, or NCI. The Fox Chase collaboration will focus on advancing the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.

ShowHide Related Items >><<
LTRN Lantern Pharma
$16.50 /

+0.2 (+1.23%)

LTRN Lantern Pharma
$16.50 /

+0.2 (+1.23%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$16.50 /

+0.2 (+1.23%)

Conference/Events
Lantern Pharma management to meet virtually with Truist » 04:55
09/11/20
09/11
04:55
09/11/20
04:55
LTRN

Lantern Pharma

$15.14 /

-0.35 (-2.26%)

Virtual Meeting to be…

Virtual Meeting to be held on September 11 hosted by Truist.

ShowHide Related Items >><<
LTRN Lantern Pharma
$15.14 /

-0.35 (-2.26%)

LTRN Lantern Pharma
$15.14 /

-0.35 (-2.26%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$15.14 /

-0.35 (-2.26%)

Conference/Events
Lantern Pharma management to meet virtually with Truist » 10:53
09/10/20
09/10
10:53
09/10/20
10:53
LTRN

Lantern Pharma

$15.15 /

-0.34 (-2.19%)

Virtual Meeting to be…

Virtual Meeting to be held on September 11 hosted by Truist.

ShowHide Related Items >><<
LTRN Lantern Pharma
$15.15 /

-0.34 (-2.19%)

LTRN Lantern Pharma
$15.15 /

-0.34 (-2.19%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$15.15 /

-0.34 (-2.19%)

Over a quarter ago
Initiation
Lantern Pharma initiated with a Buy at ThinkEquity » 06:25
08/10/20
08/10
06:25
08/10/20
06:25
LTRN

Lantern Pharma

$11.78 /

-0.525 (-4.27%)

ThinkEquity initiated…

ThinkEquity initiated coverage of Lantern Pharma with a Buy rating and $25 price target.

ShowHide Related Items >><<
LTRN Lantern Pharma
$11.78 /

-0.525 (-4.27%)

LTRN Lantern Pharma
$11.78 /

-0.525 (-4.27%)

07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$11.78 /

-0.525 (-4.27%)

Initiation
Drug 'rescuer' Lantern Pharma started at Buy at Colliers » 08:42
07/28/20
07/28
08:42
07/28/20
08:42
LTRN

Lantern Pharma

$12.40 /

-0.2 (-1.59%)

As previously reported,…

As previously reported, Colliers analyst Kyle Bauser initiated coverage of Lantern Pharma with a Buy rating and $24 price target. The company, which uses big data analytics, artificial intelligence, and machine learning to "rescue" failed or abandoned drugs, can generate highly favorable returns on investments in the context of the high costs of drug discovery, Bauser tells investors.

ShowHide Related Items >><<
LTRN Lantern Pharma
$12.40 /

-0.2 (-1.59%)

LTRN Lantern Pharma
$12.40 /

-0.2 (-1.59%)

07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
  • 11
    Jun
LTRN Lantern Pharma
$12.40 /

-0.2 (-1.59%)

Initiation
Lantern Pharma initiated with a Buy at Colliers » 08:09
07/28/20
07/28
08:09
07/28/20
08:09
LTRN

Lantern Pharma

$12.40 /

-0.2 (-1.59%)

Colliers analyst Kyle…

Colliers analyst Kyle Bauser initiated coverage of Lantern Pharma with a Buy rating and $24 price target.

ShowHide Related Items >><<
LTRN Lantern Pharma
$12.40 /

-0.2 (-1.59%)

  • 11
    Jun
LTRN Lantern Pharma
$12.40 /

-0.2 (-1.59%)

Hot Stocks
Lantern Pharma announces agreements to develop its oncology drug candidates » 07:57
07/20/20
07/20
07:57
07/20/20
07:57
LTRN

Lantern Pharma

$13.30 /

+0.33 (+2.54%)

Lantern Pharma announced…

Lantern Pharma announced entering into agreements with leading contract manufacturing companies for process development and manufacturing for two of Lantern's oncology drug candidates, LP-300 and LP-184. Lantern Pharma filed an 8-K on Thursday, July 16 describing a recent agreement for GMP manufacturing. Lantern's LP-300 is a small molecule drug candidate currently in preparation to enter phase 2 clinical trials in a growing, but unaddressed, type of non-small cell lung cancer, or NSCLC, among never-smokers.

ShowHide Related Items >><<
LTRN Lantern Pharma
$13.30 /

+0.33 (+2.54%)

  • 11
    Jun
LTRN Lantern Pharma
$13.30 /

+0.33 (+2.54%)

Hot Stocks
Lantern Pharma's AI platform for precision oncology surpasses 450M data points » 08:58
06/29/20
06/29
08:58
06/29/20
08:58
LTRN

Lantern Pharma

$11.80 /

-0.2 (-1.67%)

Lantern Pharma announced…

Lantern Pharma announced that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR. RADR leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes. Lantern is establishing collaborations and partnerships to expand the functionality of RADR, including algorithms that can operate 200 to 300 percent faster than its existing algorithms, enabling the company to develop robust gene signatures that can be used to guide patient enrollment in trials and as a companion diagnostic. During the most recent data enrichment campaign, Lantern focused on significantly increasing the depth and amount of data for: non-small cell lung cancer, ovarian cancer, glioblastoma, and gliomas. Reaching this milestone of over 450 million curated data points for oncology drug development will bring greater precision and speed in helping Lantern with its objective of personalizing oncology therapy with reduced risk and cost. As a pioneer in the application of machine learning to oncology-focused drug development and clinical trial design, Lantern has published gene signatures derived from RADR as posters and presentations at both ASCO and AACR. Lantern's pipeline of compounds includes one candidate in an active Phase 2 clinical trial for metastatic, hormone-refractory prostate cancer using a genomic signature for patient selection; another candidate in preparation for a Phase 2 clinical trial in non-small cell lung cancer in a targeted patient population; and a third candidate in two preclinical programs for biomarker-defined solid tumors and glioblastoma. Lantern Pharma is ahead of the initial platform development schedule, reaching 400 million data points by the end of 2020, which puts Lantern on track to reach over 1 billion data points earlier than expected. The developmental focus on increasing the number of data points, and improving the performance of the algorithms is expected to yield additional targeted indications for Lantern's current pipeline of drugs, and also help to uncover additional compounds and therapies that can be in-licensed or acquired and subsequently developed in a more efficient manner that leverages the insights from Lantern's data-driven, A.I.-enabled approach.

ShowHide Related Items >><<
LTRN Lantern Pharma
$11.80 /

-0.2 (-1.67%)

  • 11
    Jun
LTRN Lantern Pharma
$11.80 /

-0.2 (-1.67%)

Hot Stocks
Biological Mimetics reports 17% stake in Lantern Pharma » 07:29
06/23/20
06/23
07:29
06/23/20
07:29
LTRN

Lantern Pharma

$13.20 /

+ (+0.00%)

According to a regulatory…

According to a regulatory filing, "The purpose of the Lantern Pharma's equity grant transactions to Dr. David Silberstein was for Lantern Pharma to incentivize Dr. Silberstein to serve as a director of Lantern Pharma and to align Dr. Silberstein's interests with the interests of Lantern Pharma's stockholders. The shares of Lantern Pharma's Common Stock held directly by Biological Mimetics were acquired for investment purposes."

ShowHide Related Items >><<
LTRN Lantern Pharma
$13.20 /

+ (+0.00%)

LTRN Lantern Pharma
$13.20 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.